In pancreatic cancer, miR-133a could exert the anticarcinogenic activity by directly targeting FSCN1 [98], conversely, inhibition of miR-133a by LncRNA XIST could upregulate EGFR expression to accelerate PNI of pancreatic cancer [99]. This evidence concerns the gene EGFR and familial pancreatic carcinoma.